Publications (7)4.19 Total impact
-
Article: Recurrent autoimmune hypophysitis successfully treated with glucocorticoids plus azathioprine: a report of three cases.
[show abstract] [hide abstract]
ABSTRACT: Recurrent autoimmune hypophysitis is a rare autoimmune endocrine disease involving lymphocytic infiltration and chronic pituitary inflammation. It is even more rare than primary hypophysitis. The objective of the study was to evaluate the efficacy of glucocorticoid treatment combined with azathioprine for treating three cases of recurrent autoimmune lymphocytic hypophysitis encountered within a two-year period. The clinical features and follow-up data of these cases were analyzed, including results of treatment with glucocorticoids combined with azathioprine. All three patients were female and presented with the following clinical characteristics: case 1 was a 22-year-old with headache and diplopia; case 2 was a 70-year-old with dry mouth, polydipsia, and polyuria; case 3, a 32-year-old, with polydipsia, polyuria and menstrual disorders with headache and dizziness. Regarding recurrence, case 1 recurred 4 months after surgery and again 14 months after discontinuing prednisone; case 2 relapsed 16 months after receiving high-dose methylprednisolone pulse therapy; and case 3 recurred during the period of prednisone dose reduction. The patients were treated with glucocorticoids plus azathioprine, and positive responses were seen in all three cases. Symptoms were relieved, and MRI revealed significant reduction of lesions during follow-up. Pituitary function resumed in cases 1 and 3; permanent hypopituitarism was present in case 2. At last follow-up, MRI showed no further recurrence of disease in any patient. Treatment and responses of these patients with autoimmune hypophysitis suggest that glucocorticoid therapy combined with azothioprine is effective treatment for recurrent autoimmune hypophysitis. Endocrine and radiologic studies are an essential part of follow-up.Endocrine Journal 06/2011; 58(8):675-83. · 2.03 Impact Factor -
Article: [The role of human chorionic gonadotropin in cerebrospinal fluid in the diagnosis and treatment of intracranial germinoma].
[show abstract] [hide abstract]
ABSTRACT: To study the cerebrospinal fluid (CSF) and serum level of human chorionic gonadotropin (HCG) in patients with intracranial germinoma and to evaluate its diagnostic and therapeutic value. Thirty-one patients with intracranial germinoma receiving estimation of HCG in CSF and serum in our hospital were retrospectively analyzed in terms of HCG level, its influencing factors and the relationship of HCG with clinical features. HCG levels in CSF of the 31 cases ranged from 0.17 IU/L to 5316.98 IU/L with a median value of 3.44 IU/L. The sensitivity of diagnosis increased from 80.6% to 90.3%, when the cut point of HCG in CSF changed from 0.60 IU/L to 0.50 IU/L. The sensitivity increased from 83.9% to 93.5% when the cut point of the ratio of CSF/serum HCG decreased from 1.8 to 1.7. HCG level of germinoma located in pineal region was higher than that in basal ganglia region, while it is lowest in sellar region. The ratio of CSF/serum HCG in different parts showed no difference. Multiple risk factors analysis revealed that serum HCG (r = 0.886, P = 0.0001) and tumor size (r = 0.748, P = 0.0211) were positively correlated with the HCG level in CSF, while course of the disease, age and gender were not correlated. After radiation therapy, HCG in CSF and serum decreased dramatically as compared with those before radiation. The HCG level and its dynamic change were sensitive marker of intracranial germinomas. Based on our analysis, HCG in CSF over 0.50 IU/L and the its ratio in CSF/serum over 1.7 were highly indicative of the possibility of intracranial germinomas.Zhonghua nei ke za zhi [Chinese journal of internal medicine] 10/2010; 49(10):851-4. -
Article: Clinical and genetic analysis of the insulin receptor gene in a Chinese patient with extreme insulin resistance.
[show abstract] [hide abstract]
ABSTRACT: Several types of mutations in insulin receptor gene have been identified in patients with type A insulin resistance. A 21-year old girl was diagnosed with diabetic retinopathy and cataract after 6 years of uncontrolled diabetes. Three nucleotide substitution mutations were detected, which may be associated with the patient's extreme insulin resistance.Diabetes research and clinical practice 09/2010; 89(3):e56-8. · 2.16 Impact Factor -
Article: [Detection and clinical implication of up-regulated gene 1 mRNA levels with real-time quantitative RT-PCR in chronic lymphocytic leukemia cells.].
[show abstract] [hide abstract]
ABSTRACT: To investigate the expression level of chronic lymphocytic leukemia (CLL) up-regulated gene 1 (CLLU1) mRNA in CLL and its prognostic value in CLL. Real-time quantitative RT-PCR (qRT-PCR) was performed on 41 CLL patients using Taqman probe system. Correlation of CLLU1 expression ratio with other prognostic factors was carried out using Spearman correlation coefficient. The correlation coefficients of the standard curves in qRT-PCR were above 0.99. The coefficients of variation (CV) of interrun assay and intrarun assay were < 5% and the sensitivity reached 10(2) copies/microg RNA. The median CLLU1 mRNA expression level was 0.139 (0 - 5256.912) in 41 CLL patients. CLLU1 expression was significantly associated with Binet stages (P = 0.040) and IgVH mutation status (P = 0.021). CLLU1 expression was also associated with CD(38) expression (P = 0.045). qRT-PCR assay is reliable and sensitive. CLLU1 mRNA expression significantly correlates with clinical stages, IgVH mutation status and CD(38) expression and might be a prognostic maker of CLL.Zhonghua nei ke za zhi [Chinese journal of internal medicine] 11/2009; 48(11):947-50. -
Article: [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
[show abstract] [hide abstract]
ABSTRACT: In order to evaluate the efficiency of rituximab combined with fludarabine, cyclophosphamide and rituximab (FCR) regimen for chronic lymphocytic leukemia (CLL). Five patients with CLL were treated with FCR regimen for 2 - 6 courses. FCR regimen included fludarabine 25 mg/m(2) via intravenous drip at day 2 - 4, cyclophosphamide 250 mg/m(2) via intravenous drip at day 2 - 4 and rituximab 375 mg/m(2) via intravenous drip at day 1. Courses were repeated every 4 weeks. Minimal residual disease (MRD) was determined by multiparametic flow cytometry. The results showed that three patients achieved complete remission, 2 patients achieved partial remission. MRD was negative in two patients. In conclusion, FCR is an effective therapeutic regimen for treating CLL patients and is worth to be used in clinic.Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology 09/2008; 16(4):938-42. -
Article: [Detrimental effects of homocysteine on insulin release and apoptosis of pancreatic beta cells].
[show abstract] [hide abstract]
ABSTRACT: To study the effects of homocysteine (Hcy) on the insulin secretion and apoptosis of pancreatic beta cells. Clonal mouse pancreatic beta cells of the line NIT-1 were cultured and exposed to Hcy of 50, 100, 250, 500 and 1000 micromol/L for 6, 12, 24, and 48 hours respectively, then glucose of the concentrations of 5.6 mmol/L or 16.7 mmol/L was added for 1 h, and then the insulin concentration in the culture medium was determined by radioimmunoassay, and MTT method was used to detect the survival rate of the cells. NIT-1 cells were exposed to Hcy of the concentrations of 0, 50, 100, 250, 500 and 1000 micromol/L respectively for 24 h, another NIT-1 cells were exposed to Hcy of the final concentration of 250 micromol/L for 0, 6, 12, and 48 h respectively, then flow cytometry (FC) was used to detect the apoptosis of the cells. After exposure to Hcy of the concentrations of 50, 100, 250, 500 and 1000 micromol/L for 72 h DNA agarose gel electrophoresis was performed. Hcy inhibited the basal and glucose-induced insulin secretion in a time- and dose-dependent manner. The insulin secretion amounts of the NIT-1 cells after exposure to 50 micromol/L Hcy for 24 hours and to 100 micromol/L Hcy for 12 hours were significantly lower by 17.1% and 10.8% compared with the control group (all P < 0.01). Incubated with 100 micromol/L Hcy for 12 hours and 24 hours respectively, the survival rates of the NIT-1 cells were 94.56% and 87.93% respectively (P < 0.05, P < 0.01). Incubated with 100 micromol/L Hcy for 24 hours, the apoptosis rate of the NIT-1 cells was 7.21% (P < 0.01); and incubated with 250 micromol/L Hcy for 12 hours, the apoptosis rate of the NIT-1 cells was 12.93% (P < 0.01). Both FC and agarose gel electrophoresis indicated that Hcy induced cell apoptosis time- and concentration-dependently. Hcy impairs insulin secretion and induces cell apoptosis of pancreatic beta cells time- and concentration-dependently.Zhonghua yi xue za zhi 05/2008; 88(14):990-3. -
Article: [Effects of intervention therapy of methylcobalamin and folic acid on plasma homocysteine concentration and homocysteine thiolactonases/paraoxonase activity in patients with type 2 diabetes mellitus].
[show abstract] [hide abstract]
ABSTRACT: To study the effects of methylcobalamin and folic acid treatment on plasma homocysteine (Hcy) level and homocysteine thiolactonase/paraoxonase (HTase/PON) activity in patients with type 2 diabetes mellitus. 120 patients with type 2 diabetes mellitus were randomly divided into four equal groups: Group I, receiving no intervention therapy as control group, Group II, given folic acid orally (5 mg/d), Group III, receiving intramuscular injection of methylcobalamin (500 microg qd), and Group IV, treated with methylcobalamin (500 microg qd) in addition to folic acid (5 mg/d). Forty healthy age-matched persons were used as normal controls. Before and 12 weeks after 2-week treatment, plasma total Hcy, vitamin B(12), folic acid, and HTase/PON activity were assayed. After 12-week treatment the plasma folic acid and methylcobalamin, and Hcy levels decreased and serum HTase/PON activity increased significantly in the three groups receiving intervention treatment (all P < 0.05). The Hcy level decreased by 2.8% in Group I, 14.0% in Group II, 37.3% in Group III, and 21.7% in Group IV respectively (all P < 0.01). The HTase/PON activity increased by 2.7% in Group I, 8.0% in Group II, 3.4% in Group III, and 17.6% in Group IV respectively (all P < 0.05). Methylcobalamin and folic acid treatment alone can decrease the Hcy level and increase the HTase/PON activity in the patients with type 2 diabetes mellitus, and the methylcobalamin and folic acid combination therapy is much more effective. Folic acid may affect the HTase/PON activity through its antioxidant ability.Zhonghua yi xue za zhi 01/2007; 87(4):256-8.
Top co-authors
Top Journals
Institutions
-
2010–2011
-
Chinese PLA General Hospital
Beijing, Beijing Shi, China
-
-
2007–2010
-
307 Hospital of the Chinese People's Liberation Army
Beijing, Beijing Shi, China
-
-
2008–2009
-
Nanjing Medical University
- Department of Hematology
Nanjing, Jiangsu Sheng, China
-
